Frapolli R - Search Results

1

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Germano G, et al. Among authors: frapolli r. Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. Nature. 2017. PMID: 29186113 Free article.

2

High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma.

Colombo T, Frapolli R, Bombardelli E, Morazzoni P, Riva A, D'Incalci M, Zucchetti M. Colombo T, et al. Among authors: frapolli r. J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):135-41. doi: 10.1016/s0378-4347(99)00450-8. J Chromatogr B Biomed Sci Appl. 1999. PMID: 10676993

3

Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.

Tognon G, Frapolli R, Zaffaroni M, Erba E, Zucchetti M, Faircloth GT, D'Incalci M. Tognon G, et al. Among authors: frapolli r. Cancer Chemother Pharmacol. 2004 Jan;53(1):89-90. doi: 10.1007/s00280-003-0704-y. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586558 No abstract available.

4

Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.

Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M. Frapolli R, et al. Drug Metab Dispos. 2006 Dec;34(12):2028-35. doi: 10.1124/dmd.106.012153. Epub 2006 Sep 8. Drug Metab Dispos. 2006. PMID: 16963486

5

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.

Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, D'Incalci M, Ryan AJ, Giavazzi R. Cesca M, et al. Among authors: frapolli r. Neoplasia. 2009 Nov;11(11):1155-64. doi: 10.1593/neo.09866. Neoplasia. 2009. PMID: 19881951 Free PMC article.

6

The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo.

Brunelli D, Tavecchio M, Falcioni C, Frapolli R, Erba E, Iori R, Rollin P, Barillari J, Manzotti C, Morazzoni P, D'Incalci M. Brunelli D, et al. Among authors: frapolli r. Biochem Pharmacol. 2010 Apr 15;79(8):1141-8. doi: 10.1016/j.bcp.2009.12.008. Epub 2009 Dec 16. Biochem Pharmacol. 2010. PMID: 20006591

7

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M. Frapolli R, et al. Eur J Cancer. 2010 Feb;46(3):505-16. doi: 10.1016/j.ejca.2009.11.006. Epub 2009 Dec 16. Eur J Cancer. 2010. PMID: 20007015 Clinical Trial.

8

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

Frapolli R, Tamborini E, Virdis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, Gronchi A, Tercero JC, Peloso G, Casali P, Pilotti S, D'Incalci M. Frapolli R, et al. Clin Cancer Res. 2010 Oct 15;16(20):4958-67. doi: 10.1158/1078-0432.CCR-10-0317. Epub 2010 Aug 20. Clin Cancer Res. 2010. PMID: 20732964

9

Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells.

Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, Favero F, Mello-Grand M, Dei Tos AP, Giulotto E, Taraboletti G, D'Incalci M, Mondello C. Belgiovine C, et al. Among authors: frapolli r. PLoS One. 2010 Nov 30;5(11):e14154. doi: 10.1371/journal.pone.0014154. PLoS One. 2010. PMID: 21209796 Free PMC article.

10

The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.

D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A. D'Angelo D, et al. Among authors: frapolli r. Eur J Cancer. 2013 Mar;49(5):1142-51. doi: 10.1016/j.ejca.2012.10.014. Epub 2012 Nov 10. Eur J Cancer. 2013. PMID: 23149213

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82 results

Search Page